Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis

We identified analytic limitations in a recent meta‐analysis and re‐examined the efficacy and safety associated with immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma (HCC) compared with standard therapies. Our findings mostly contradict conclusions from the previous study...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shouhao, Shen, Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958338/
https://www.ncbi.nlm.nih.gov/pubmed/36852153
http://dx.doi.org/10.1002/jgh3.12856
_version_ 1784895001160843264
author Zhou, Shouhao
Shen, Chan
author_facet Zhou, Shouhao
Shen, Chan
author_sort Zhou, Shouhao
collection PubMed
description We identified analytic limitations in a recent meta‐analysis and re‐examined the efficacy and safety associated with immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma (HCC) compared with standard therapies. Our findings mostly contradict conclusions from the previous study, suggesting the need for continuing the investigation of ICIs in HCC with additional clinical evidence.[Image: see text]
format Online
Article
Text
id pubmed-9958338
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wiley Publishing Asia Pty Ltd
record_format MEDLINE/PubMed
spelling pubmed-99583382023-02-26 Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis Zhou, Shouhao Shen, Chan JGH Open Brief Report We identified analytic limitations in a recent meta‐analysis and re‐examined the efficacy and safety associated with immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma (HCC) compared with standard therapies. Our findings mostly contradict conclusions from the previous study, suggesting the need for continuing the investigation of ICIs in HCC with additional clinical evidence.[Image: see text] Wiley Publishing Asia Pty Ltd 2023-01-24 /pmc/articles/PMC9958338/ /pubmed/36852153 http://dx.doi.org/10.1002/jgh3.12856 Text en © 2023 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Zhou, Shouhao
Shen, Chan
Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis
title Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis
title_full Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis
title_fullStr Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis
title_full_unstemmed Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis
title_short Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis
title_sort efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a re‐analysis of a meta‐analysis
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958338/
https://www.ncbi.nlm.nih.gov/pubmed/36852153
http://dx.doi.org/10.1002/jgh3.12856
work_keys_str_mv AT zhoushouhao efficacyandsafetyassociatedwithimmunecheckpointinhibitorsinunresectablehepatocellularcarcinomaareanalysisofametaanalysis
AT shenchan efficacyandsafetyassociatedwithimmunecheckpointinhibitorsinunresectablehepatocellularcarcinomaareanalysisofametaanalysis

Ejemplares similares